Micro environmental pH-Modulated Dissolution in Functional Pellet Cores

Introduction to Micro environmental pH-Modulated Dissolution

Micro environmental pH-modulated dissolution describes an approach in controlled oral drug delivery where the internal pH of a multiparticulate system is actively altered to enhance the release of a weakly basic drug at higher gastrointestinal pH. Weakly basic active pharmaceutical ingredients (APIs) often dissolve well at low pH but show poor solubility in the near-neutral to alkaline portions of the intestine. Some drugs of this API class are listed elsewhere [1]. To address this challenge, formulators incorporate organic acids into multiparticulate cores to create a localized acidic environment that persists during dissolution. The following information are generally based on a publication by K. Vlahovic, et al [2].
Functional pellet cores composed predominantly of tartaric acid exemplify this strategy. When coated with drug layers and controlled-release polymers, these cores modify local pH conditions and thus influence API dissolution kinetics throughout the gastrointestinal tract.

Rationale for Functional Tartaric Acid Cores

pH Influence on Weakly Basic Drug Solubility

Tartaric acid acts as a pH modifier because it dissociates in aqueous environments and lowers local pH around the pellet core. For APIs with pH-dependent solubility, such as Albendazole EP, an acidic micro environment enhances solubility at higher pH values typical of the small intestine and colon. Weakly basic compounds dissolve poorly at neutral or alkaline pH, which limits their bioavailability in those regions.
A functional core that releases tartaric acid only at controlled rates can sustain a lower pH adjacent to the drug layers. This approach contrasts with inert cores that provide no pH modulation and thus fail to improve dissolution where it is most needed.

Mechanisms of Controlled Release

Formulators build multilayer systems by first layering the API onto tartaric acid pellets (TAP). In this case, a TAP® 700 (600–800 μm; IPC Process-Center GmbH, Dresden, Germany) is used. Subsequently, they apply combinations of time-dependent and pH-dependent polymer coatings. Time-dependent polymers retard the penetration of dissolution media and delay both acid and drug release. Meanwhile, pH-dependent coatings remain intact until the formulation reaches specific pH thresholds in the intestine, where they then dissolve and permit core interaction with the surrounding fluid. Together, these coatings preserve an internally acidic environment long enough to enhance drug release at elevated pH.

Formulation Development

Core Characteristics

Pellet cores composed entirely of tartaric acid possess high solubility and the ability to generate an acidic micro environment upon interaction with dissolution media. The dissociation constants of tartaric acid (pKa values approximately 2.93 and 4.23) make it effective in acidifying its immediate surroundings within multiparticulates.
Manufacturers select core sizes and shapes that support uniform coating and predictable layer deposition. Uniform sphericity and narrow particle size distributions enhance reproducibility in drug layering and polymer application steps.

Coating Architecture

To achieve micro environmental pH-modulated dissolution, formulators apply drug layers to the tartaric acid core using fluidized bed techniques. For example references of fluidized bed process technologies, please refer elsewhere [3]. After API layering, they introduce sequential polymer coatings. A time-dependent polymer layer slows ingress of dissolution media and supports delayed action. Next, a pH-dependent polymer exposes the functional core once the formulation exits the stomach. This polymer is typically designed to dissolve at near-intestinal pH.

This layered system aims first to prevent premature drug release at low pH, and then to maintain an acidic micro environment at higher pH for enhanced dissolution. Accordingly, the controlled interplay of core acidification and polymer dissolution supports consistent API release in the target region.

Comparative Performance

Experimental systems using functional tartaric acid cores demonstrate improved release of weakly basic drugs at elevated pH. In special this counts when comparing with similar systems built on inert cores such as sugar spheres or microcrystalline cellulose. Unlike inert cores, tartaric acid cores maintain localized acidity long enough to alter API dissolution in otherwise unfavorable conditions.

Furthermore, combining time-dependent and pH-dependent coatings enhances the ability to prevent premature acid loss. This integrated approach leads to more predictable and sustained dissolution profiles. Mainly, that’s reached by ensuring that tartaric acid remains within the pellet core until the polymer barriers dissolve at the intended pH trigger.

Micro Environmental pH Evaluation

The micro environmental pH within coated pellets can be assessed using slurry or microfluidic cell techniques. These techniques reveal how coatings regulate acid diffusion and subsequent pH changes inside the pellet. When well formulated, the functional core sustains low pH conditions within the system as the dissolution medium penetrates. Thereby it supports increased API solubility at higher external pH.
Colorimetric indicators and pH measurements confirm that tartaric acid remains within the pellet core under controlled conditions. This further supports the efficacy of micro environmental modulation.

Conclusions

Micro environmental pH-modulated dissolution harnesses the chemical properties of tartaric acid to create localized acidic conditions that improve the dissolution of weakly basic APIs in near-neutral to alkaline environments. Functional tartaric acid cores, when integrated with proper coating technologies, enhance solubility and contribute to predictable extended release profiles. Compared to inert cores, these systems improve performance where pH otherwise limits drug release. The strategic use of time-dependent and pH-dependent polymers ensures that core acidification remains effective until the drug has been sufficiently released.

References

[1] BSC Class IV APIs in oral formulations

[2] K. Vlahovic, et al., Pharmaceutics 2025, 17(9), 1133; doi: 10.3390/pharmaceutics17091133

[3] Fluidized bed systems (external link to Glatt GmbH, Germany)